Compare RVPH & BHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | BHAT |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 59.1M |
| IPO Year | N/A | 2019 |
| Metric | RVPH | BHAT |
|---|---|---|
| Price | $0.60 | $1.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 4.6M | 71.0K |
| Earning Date | 11-13-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,972,415.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $1.07 |
| 52 Week High | $2.17 | $24.50 |
| Indicator | RVPH | BHAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 44.61 |
| Support Level | $0.48 | $1.19 |
| Resistance Level | $0.67 | $1.60 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 37.46 | 35.56 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.